GSK

GSK R&D Expenses

£9.20BTTM · GBP

Period ending:

GSK FY R&D ExpensesGBP
GSK FY R&D Expenses1986-06-30: £113.00M1987-06-30: £149.00M1988-06-30: £230.00M1989-06-30: £323.00M1990-06-30: £420.00M1991-06-30: £475.00M1992-06-30: £595.00M1993-06-30: £739.00M1994-06-30: £858.00M1995-06-30: £0.001995-12-31: £1.54B1996-12-31: £1.16B1997-12-31: £1.15B1998-12-31: £1.16B1999-12-31: £1.27B2000-12-31: £2.53B2001-12-31: £2.56B2002-12-31: £2.90B2003-12-31: £2.79B2004-12-31: £2.90B2005-12-31: £3.14B2006-12-31: £3.46B2007-12-31: £3.24B2008-12-31: £3.68B2009-12-31: £4.11B2010-12-31: £4.46B2011-12-31: £4.01B2012-12-31: £3.98B2013-12-31: £3.92B2014-12-31: £3.45B2015-12-31: £3.56B2016-12-31: £3.63B2017-12-31: £4.48B2018-12-31: £3.89B2019-12-31: £4.57B2020-12-31: £4.79B2021-12-31: £5.02B2022-12-31: £5.49B2023-12-31: £6.22B2024-12-31: £6.40B2025-12-31: £7.53B£7.53B£0.00
1986-06-302025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in GBP. Dates are period ends; a fiscal year may differ from a calendar year.

GSK r&d expenses history

Research and development spending. The available annual fiscal periods series contains 41 observations from Jun 30, 1986 to Dec 31, 2025.

GSK plc American Depositary Shares (Each representing two Ordinary Shares) R&D Expenses — Annual fiscal periods (GBP)
Period endingR&D Expenses (GBP)
7,525,000,000
6,401,000,000
6,223,000,000
5,488,000,000
5,019,000,000
4,793,000,000
4,568,000,000
3,893,000,000
4,476,000,000
3,628,000,000
3,560,000,000
3,450,000,000
3,923,000,000
3,979,000,000
4,009,000,000
4,457,000,000
4,106,000,000
3,681,000,000
3,240,311,000
3,455,986,000
3,135,358,000
2,902,932,000
2,787,120,000
2,900,000,000
2,560,904,000
2,526,000,000
1,269,000,000
1,163,000,000
1,148,000,000
1,161,000,000
1,540,000,000
0
858,000,000
739,000,000
595,000,000
475,000,000
420,000,000
323,000,000
230,000,000
149,000,000
113,000,000

Compare r&d expenses

All GSK financial metrics · GSK stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.